Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
April 18, 2023 16:01 ET
|
Arbutus Biopharma Corporation
Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical...
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 04, 2023 07:52 ET
|
Arbutus Biopharma Corporation
Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
March 16, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical...
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
March 14, 2023 16:05 ET
|
Arbutus Biopharma Corporation
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14,...
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
March 02, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for...
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
February 16, 2023 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Participate in Three Upcoming Investor Conferences
February 06, 2023 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces Resignation of Board Member
January 27, 2023 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
January 05, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into...
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
December 13, 2022 07:30 ET
|
Arbutus Biopharma Corporation
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE...